ALN HSD
Alternative Names: ALN-HSDLatest Information Update: 19 Mar 2024
At a glance
- Originator Alnylam Pharmaceuticals; Regeneron Pharmaceuticals
- Class Hepatoprotectants; Ribonucleosides; Small interfering RNA
- Mechanism of Action Hydroxysteroid dehydrogenase expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
Most Recent Events
- 07 Mar 2024 Alnylam Pharmaceuticals terminates a phase I trial in Non-alcoholic steatohepatitis in USA, the UK, Turkey, Bulgaria, and Belgium (SC) (NCT04565717)
- 21 Jun 2023 Pharmacokinetics and safety data from a phase I trial in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
- 21 Feb 2023 ALN HSD is still in preclinical study for Non-alcoholic steatohepatitis (SC, Injection) in the USA